In vivo CRISPR gene editing has produced its first positive Phase 3 result. Intellia Therapeutics says a single infusion of lonvoguran ziclumeran, or lonvo-z, sharply reduced attacks of hereditary angioedema in a randomised trial. If regulators agree with the evidence, it could become the first approved treatment that edits genes directly inside the body.
The result is a landmark for biotechnology, but it is not a universal gene-editing breakthrough. Lonvo-z targets one gene in liver cells for one rare disease, and longer follow-up remains essential.
What hereditary angioedema does
Hereditary angioedema, or HAE, causes unpredictable episodes of severe swelling. Attacks can affect the hands, feet, face, abdomen and airway. Many people use long-term preventive medicines or emergency treatment when an attack begins.
Lonvo-z is designed to inactivate the KLKB1 gene in liver cells. That gene helps produce plasma kallikrein, part of a pathway that can generate excessive bradykinin and trigger swelling. The treatment packages CRISPR components in lipid nanoparticles that travel mainly to the liver.
What the HAELO Phase 3 trial found
The HAELO trial enrolled 80 people: 52 received a single 50-milligram dose of lonvo-z and 28 received placebo. From weeks five to 28, the mean monthly attack rate was 0.26 with lonvo-z and 2.10 with placebo—an 87% reduction.
Sixty-two per cent of treated participants were both attack-free and free from long-term preventive therapy during that six-month evaluation period, compared with 11% in the placebo group. Intellia reported that adverse events in the treated group were mild or moderate through the data cut-off; common events included infusion reactions, headache and fatigue.
Why this result is different
The first approved CRISPR treatment edits a patient’s blood-forming cells outside the body and returns them after conditioning. Lonvo-z edits cells in place. That could make treatment simpler, but it also raises a demanding safety question: an edit intended to last for years cannot simply be withdrawn.
Researchers therefore need long-term data on durability, liver safety, immune responses and unintended edits. The Phase 3 comparison lasted six months for the primary analysis, which is enough to test attack frequency but not every delayed risk.
Lonvo-z regulatory review and long-term monitoring
Intellia initiated a rolling biologics licence application with the US Food and Drug Administration. A successful trial does not guarantee approval; regulators will review manufacturing, safety, benefit and long-term monitoring plans.
The larger significance is that in vivo editing has now passed a late-stage controlled test. If lonvo-z is approved and remains safe over time, it could strengthen the case for one-time genetic medicines targeting other liver-produced proteins. Each new target will still require its own evidence.
A related approach is being studied in cholesterol base editing with VERVE-102, where a Phase 1b trial is testing a different type of gene edit in the liver.
Sources and further reading
- Intellia: HAELO Phase 3 topline results
- Intellia: additional HAELO analyses and journal publication
- ClinicalTrials.gov: HAELO, NCT06634420
Reporting note: Intellia develops lonvo-z. Company-reported results require regulatory review and longer follow-up. This article is informational and does not provide medical or investment advice.
Leave a Reply